The South Korea AI Radiology Reimbursement Market was valued at approximately USD 268.4 million. It is projected to grow at a CAGR of around 18.4% during the forecast period of 2026–2030, reaching an estimated USD 624.51 million by 2030.
The South Korea AI Radiology Reimbursement Market is about how AI radiology solutions get paid for in the healthcare system. This market includes all the ways that AI solutions used in radiology get reimbursed like diagnostic imaging interpretation and workflow optimization. It does not include healthcare AI applications or software solutions that are not related to radiology.
The market is changing from talking about adopting new technology to talking about how to pay for it and show its value. Healthcare providers are starting to care about whether AI solutions can fit into the existing payment system and make a difference in how they work. As the number of imaging tests keeps going up and radiologists get busier people are looking for solutions that can help them work efficiently and accurately.
This change is affecting how people make decisions in the healthcare industry. Technology developers are working harder to show that their solutions work. Can get paid for while healthcare providers are being more careful about what they buy. For people who invest in healthcare, payers and healthcare institutions understanding how reimbursement works is crucial for figuring out if a solution can be successful and sustainable.
Key Market Insights
Research Methodology
Scope & Definitions
Evidence Collection (Primary + Secondary)
Triangulation & Validation
Presentation & Auditability
South Korea AI Radiology Reimbursement Market Drivers
Rising imaging workloads are accelerating demand for intelligent automation.
One of the reasons AI radiology solutions are being used more is that there are too many imaging tests for radiologists to handle. This means that there is a growing need for automation and AI tools that can help with image analysis and workflow optimization. As healthcare providers try to modernize their operations, reimbursement is becoming a factor in whether they can use these solutions more widely.
Healthcare digital transformation initiatives are supporting reimbursable AI adoption.
The healthcare industry in South Korea is also going through a transformation, which is helping to increase the use of AI radiology solutions that can get reimbursed. Radiology is one of the areas where AI is being used the most because it can help with workflow consistency and decision support. As people start to see the benefits of AI in radiology, reimbursement pathways are being created to help healthcare providers use these solutions in their work.
Outcome-focused payment models are encouraging clinical AI utilization.
Another trend that is helping to increase the use of AI radiology solutions is the move towards payment models that focus on outcomes. Healthcare stakeholders are starting to care about whether solutions can show they are making a difference in patient care and outcomes. This means that reimbursement frameworks are starting to reward technologies that can demonstrate they are contributing to healthcare outcomes.
South Korea AI Radiology Reimbursement Market Restraints
Even though AI-assisted radiology is becoming more popular, there are still some challenges to overcome, like reimbursement uncertainty. Healthcare providers often have to go through a process to get reimbursed, and there are inconsistent requirements for economic evidence. There are also costs associated with integrating AI solutions and concerns about whether clinicians will adopt them. As payment frameworks evolve and there is validation of real-world outcomes, these challenges can slow down the wider use of AI radiology solutions.
South Korea's AI Radiology Reimbursement Market Opportunities
Despite these challenges, there are still opportunities for growth in the South Korean AI radiology reimbursement market. Expanding reimbursement pathways for validated imaging algorithms can help to increase the use of AI radiology solutions. As there is a growing need for image interpretation, broader integration into cancer and neurological care pathways, and more emphasis on outcome-based healthcare funding, AI radiology solutions are well-positioned to get more reimbursement and adoption.
Developers create AI applications for specific radiology workflows and imaging modalities.
Clinical studies generate evidence related to diagnostic accuracy, workflow impact, and patient outcomes.
Solutions undergo regulatory review before commercial deployment within South Korea.
Health technology evaluation determines whether the solution demonstrates sufficient clinical and economic value.
Relevant reimbursement authorities assess eligibility, payment mechanisms, and coverage conditions.
Public and private payers evaluate funding implications and reimbursement structures.
Hospitals compare reimbursed and non-reimbursed solutions based on operational and financial considerations.
Healthcare providers select solutions that align with clinical priorities and reimbursement realities.
AI tools become integrated into imaging workflows across hospitals and diagnostic centers.
Providers receive reimbursement through applicable payment mechanisms and healthcare funding channels.
Why this market matters now
Many healthcare AI markets assume regulatory approval is the primary commercial milestone. In practice, reimbursement often determines whether adoption scales.
South Korean healthcare providers face pressure to improve efficiency while managing resource constraints. Radiology departments continue to handle growing imaging volumes, while healthcare systems seek measurable productivity gains without compromising quality.
At the same time, AI developers face a more demanding environment. Investors increasingly scrutinize reimbursement visibility rather than focusing solely on technological capability. Hospitals are becoming more selective, requiring stronger evidence before allocating budgets.
This creates a market where reimbursement pathways, evidence generation, and adoption economics have become tightly connected. Stakeholders that understand these relationships are better positioned to allocate capital, prioritize partnerships, and manage commercialization risk.
What matters most when evaluating claims in this market
|
Claim type |
What good proof looks like |
What often goes wrong |
|
Clinical effectiveness |
Peer-reviewed outcomes and real-world validation |
Reliance on small pilot studies |
|
Reimbursement potential |
Documented assessment pathway and payer engagement |
Assuming approval guarantees reimbursement |
|
Hospital demand |
Procurement evidence and deployment experience |
Using interest as a proxy for adoption |
|
Revenue opportunity |
Reimbursed utilization analysis |
Counting non-reimbursed deployments |
|
Market growth |
Multiple validated data sources |
Double counting across value chains |
|
Competitive position |
Demonstrated workflow integration |
Overstating technical differentiation |
The decision lens
1. Define Market Boundary
Verify whether revenues represent reimbursed AI radiology activity rather than broader healthcare AI markets.
2. Assess Approval Path
Compare regulatory status, assessment requirements, and reimbursement readiness.
3. Validate Evidence Quality
Review clinical validation, economic evidence, and real-world deployment results.
4. Compare Payer Exposure
Analyze dependence on public reimbursement, private coverage, and alternative funding mechanisms.
5. Stress-Test Adoption
Evaluate hospital purchasing behavior under different reimbursement scenarios.
6. Examine Timing Risk
Identify delays that could emerge from regulatory, assessment, or reimbursement processes.
7. Model Revenue Realism
Test revenue assumptions against actual reimbursement eligibility and provider utilization.
The contrarian view
Many market discussions overestimate the importance of regulatory approval and underestimate reimbursement complexity.
Another common mistake is counting every deployed AI radiology tool as part of the reimbursed market. Many solutions may operate without dedicated reimbursement support.
Some analyses also treat all imaging modalities as commercially equivalent. In reality, reimbursement pathways and evidence requirements can differ significantly.
Double counting frequently occurs when revenues are measured simultaneously across software providers, healthcare providers, and reimbursement streams.
The most reliable market assessments focus on reimbursed value creation rather than technology availability alone.
Practical implications by stakeholder
AI Radiology Vendors
Hospitals
Investors
Payers
Diagnostic Imaging Centers
Healthcare Policymakers
SOUTH KOREA AI RADIOLOGY REIMBURSEMENT MARKET REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2025 - 2030 |
|
Base Year |
2025 |
|
Forecast Period |
2026 - 2030 |
|
CAGR |
18.4% |
|
Segments Covered |
By Reimbursement Payer Type , Imaging Modality Covered ,. Clinical Radiology Use Case , AI Reimbursement Mechanism, Healthcare Provider , and Region |
|
Various Analyses Covered |
Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regional Scope |
south korea |
|
Key Companies Profiled |
Lunit, VUNO, JLK, Deepnoid, Coreline Soft, AIDOC, Qure.ai, Siemens Healthineers, GE HealthCare, Philips, Fujifilm Healthcare, Canon Medical Systems, Samsung Medison, InferVision, and Riverain Technologies. |
South Korea AI Radiology Reimbursement Market Segmentation
The National Health Insurance Service or NHIS is the player in the market with 58% share in 2026. This is because the National Health Insurance Service plays a role in paying for AI radiology solutions that are reimbursed. The National Health Insurance Service covers a lot of people. Has a system in place to pay for these solutions, which helps them get used more widely.
Private Health Insurance is growing fast with a growth rate of 21.3% until 2030. This is because more people want to use diagnostic services and get extra coverage. This means that there are chances for AI imaging to get paid for.
South Korea AI Radiology Reimbursement Market – By Imaging Modality Covered
One way that AI radiology solutions get paid for is by adding on to the cost of an imaging procedure. This accounts for 33% of the market revenue making it the common way that these solutions get paid for. Healthcare providers like this way of paying for AI radiology solutions because it fits with the way they already pay for things.
Another way that AI radiology solutions are getting paid for is through value-based reimbursement models. These models are growing fast with a growth rate of 25.4% from 2026 to 2030. This is because people are starting to care about getting good results from healthcare and making sure that healthcare is efficient. This means that payment models are starting to reward technologies that can show they are making a difference.
The Seoul Metropolitan Area is the market with 46% share. This is because there are a lot of hospitals and research centers in this area and they have good imaging infrastructure. The Seoul Metropolitan Area is also investing a lot in healthcare innovation. Is one of the first places to use AI in radiology which helps with reimbursement.
The Gyeonggi Province is growing fast with a growth rate of 22.9% until 2030. This is because there are hospitals and imaging centers being built and more people are using AI-assisted diagnostics. This means that there are chances for AI radiology solutions to get paid for.
Latest Market News
On Jan 15, 2026, Korean hospitals that provide advanced medical care expanded the use of artificial intelligence-assisted chest imaging workflows that are covered by insurance with 2 approved ways to use these systems in clinics and a 3-year window to get insurance money back, which helps more hospitals decide to use these systems.
Sep 30, 2025: Artificial intelligence-enabled radiology solutions that support breast imaging and chest X-ray analysis were used in more than 2 major clinical screening programs, and hospitals could still get insurance money back for using these systems under special rules for new technology.
Jul 02, 2025: Lunit announced that it is working with Microsoft, combining 2 artificial intelligence platforms for healthcare and using 1 global cloud system to help put artificial intelligence in radiology more quickly.
On May 21, 2025, Dongkook Lifescience and Myongji Hospital worked together closely by adding 2 artificial intelligence imaging solutions that cover chest radiography and mammography after they first agreed to work together in 2024.
On May 07, 2025, Lunit started a partnership with Starvision that will last for 5 years, covering 79 radiology sites and many kinds of imaging.
Apr 15, 2025: Lunit signed an agreement with GC i-Med to use its system in two health-screening clinics and to use artificial intelligence to help analyze chest X-rays and mammography in care.
Mar 18, 2025: Lunit got a 5-year contract with a healthcare network that has more than 14 hospitals and over 70 healthcare facilities to provide artificial intelligence-supported mammography services.
Key Players
Questions buyers ask before purchasing this report
How does reimbursement influence AI radiology adoption in South Korea?
Reimbursement often determines whether hospitals can justify widespread deployment. While regulatory approval enables commercialization, reimbursement creates the financial pathway that supports scaling. Understanding this relationship is essential for forecasting market growth and adoption patterns.
Why is the MFDS-HIRA-nHTA sequence important?
The approval and assessment pathway influences market access timing, reimbursement eligibility, and commercialization risk. Delays or challenges at any stage can affect adoption rates, revenue realization, and investment outcomes.
Which imaging modalities create the strongest reimbursement opportunities?
Different modalities face different evidence requirements, clinical priorities, and reimbursement conditions. The report evaluates these distinctions to identify where commercial opportunities may emerge most effectively.
How do hospitals decide between paid and non-paid AI imaging tools?
Hospitals assess clinical value, workflow impact, operational efficiency, reimbursement availability, implementation costs, and long-term sustainability. Financial viability often becomes a deciding factor.
What risks do investors overlook in this market?
Many investors focus heavily on technology performance while underestimating reimbursement complexity, evidence requirements, and adoption barriers. These factors can significantly influence commercial outcomes.
How should vendors evaluate market entry timing?
Market entry decisions should consider regulatory readiness, reimbursement pathways, hospital procurement behavior, and evidence maturity. Timing mistakes can increase commercialization costs and delay revenue generation.
What makes market sizing difficult in AI radiology reimbursement?
The biggest challenge is separating reimbursed activity from broader AI healthcare revenues. Accurate market sizing requires strict boundaries, validated reimbursement data, and careful avoidance of double counting.
Why do healthcare providers need reimbursement-specific market intelligence?
Provider decisions increasingly depend on understanding how reimbursement structures influence technology adoption, budget allocation, workflow efficiency, and long-term financial sustainability.
The South Korea AI Radiology Reimbursement Market was valued at approximately USD 268.4 million. It is projected to grow at a CAGR of around 18.4% during the forecast period of 2026–2030, reaching an estimated USD 624.51 million by 2030.
The major drivers of the South Korea AI Radiology Reimbursement Market include rising imaging workloads across healthcare facilities, increasing demand for workflow automation, and ongoing healthcare digital transformation initiatives. Healthcare providers are increasingly adopting AI-assisted radiology solutions to improve diagnostic efficiency, enhance workflow consistency, and support clinical decision-making. Additionally, the growing focus on outcome-based healthcare delivery, expanding reimbursement pathways for validated imaging algorithms, and the need to address radiologist workload pressures continue to accelerate market growth across South Korea.
National Health Insurance Service (NHIS), Private Health Insurance, Employer-Sponsored Health Programs, Government-Funded Special Healthcare Programs, and Others are the segments under the South Korea AI Radiology Reimbursement Market by Reimbursement Payer Type. Computed Tomography (CT), Magnetic Resonance Imaging (MRI), X-ray Imaging, Mammography, Ultrasound Imaging, Nuclear Imaging (PET/SPECT), and Others are the segments by Imaging Modality Covered. Oncology Imaging, Neurology Imaging, Cardiovascular Imaging, Pulmonary & Thoracic Imaging, Musculoskeletal Imaging, Breast Imaging, and Others are the segments by Clinical Radiology Use Case. Separate AI Procedure Reimbursement, Add-on Reimbursement to Imaging Procedure, Bundled Reimbursement within Diagnostic Workflow, Value-Based Reimbursement Models, Pilot & Innovation Funding Programs, and Others are the segments by AI Reimbursement Mechanism. Tertiary General Hospitals, General Hospitals, Specialty Diagnostic & Imaging Centers, Public Healthcare Institutions, Academic & University Hospitals, and Others are the segments by Healthcare Provider Category. Seoul Metropolitan Area, Gyeonggi Province, Busan Metropolitan Area, Daegu-Gyeongbuk Region, and Rest of South Korea are the regional segments under the South Korea AI Radiology Reimbursement Market.
The Seoul Metropolitan Area is the most dominant region in the South Korea AI Radiology Reimbursement Market, supported by its concentration of tertiary hospitals, academic medical centers, advanced imaging infrastructure, and strong adoption of AI-enabled radiology solutions. Gyeonggi Province is expected to be the fastest-growing region during the forecast period of 2026–2030, driven by expanding healthcare infrastructure, increasing deployment of AI-assisted diagnostic technologies, and growing investment in healthcare modernization. The remaining regions across South Korea continue to experience steady growth due to broader digital healthcare adoption and increasing utilization of AI-supported imaging solutions.
The key players in the South Korea AI Radiology Reimbursement Market include Lunit, VUNO, JLK, Deepnoid, Coreline Soft, AIDOC, Qure.ai, Siemens Healthineers, GE HealthCare, Philips, Fujifilm Healthcare, Canon Medical Systems, Samsung Medison, InferVision, and Riverain Technologies.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Specify your preferred Countries, Segments, or timeframes
Unlock Country Level Outlook, Trends, Cross-country Comparability, or supply Chain Variations.
Analyst Support
Every order comes with Analyst Support.
Customization
We offer customization to cater your needs to fullest.
Verified Analysis
We value integrity, quality and authenticity the most.
